Genetic progression and divergence in pancreatic carcinoma
about
Palladin mutation causes familial pancreatic cancer and suggests a new cancer mechanismHIN-1, a putative cytokine highly expressed in normal but not cancerous mammary epithelial cellsWhat is the origin of pancreatic adenocarcinoma?Targeted destruction of the orchestration of the pancreatic stroma and tumor cells in pancreatic cancer cases: molecular basis for therapeutic implicationsWhole-exome sequencing of human pancreatic cancers and characterization of genomic instability caused by MLH1 haploinsufficiency and complete deficiencyExdpf is a key regulator of exocrine pancreas development controlled by retinoic acid and ptf1a in zebrafish.KLF4 is a novel candidate tumor suppressor gene in pancreatic ductal carcinoma.Precursor lesions of pancreatic cancer.Genetic progression in the pancreatic ducts.Utilization of ancillary studies in the cytologic diagnosis of biliary and pancreatic lesions: The Papanicolaou Society of Cytopathology Guidelines.Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma.Update on pancreatic intraepithelial neoplasia.Loss of p16INK4a results in increased glucocorticoid receptor activity during fibrosarcoma development.Pathological appraisal of lines of resection for bile duct carcinoma.Utilization of ancillary studies in the cytologic diagnosis of biliary and pancreatic lesions: the Papanicolaou Society of Cytopathology guidelines for pancreatobiliary cytologyPancreatic cancer stromal biology and therapy.The pathology of ductal-type pancreatic carcinomas and pancreatic intraepithelial neoplasia: insights for clinicians.Allelic loss is often the first hit in the biallelic inactivation of the p53 and DPC4 genes during pancreatic carcinogenesisLoss of heterozygosity or intragenic mutation, which comes first?Advances in biomarker research for pancreatic cancer.Molecular genetics of pancreatic ductal adenocarcinomas and recent implications for translational efforts.Stromal biology of pancreatic cancer.Molecular genetics of pancreatic intraepithelial neoplasia.Genetic alterations in pancreatic cancer.Epigenetics and epigenetic alterations in pancreatic cancer.Emerging molecular biology of pancreatic cancer.The molecular biology of pancreatic cancer.Transcriptomic and CRISPR/Cas9 technologies reveal FOXA2 as a tumor suppressor gene in pancreatic cancer.Loss of heterozygosity and microsatellite instability as predictive markers among Iranian esophageal cancer patients.Microsatellite alterations in phenotypically normal esophageal squamous epithelium and metaplasia-dysplasia-adenocarcinoma sequence.In vitro models of pancreatic cancer for translational oncology research.Pancreatic intraepithelial neoplasia-can we detect early pancreatic cancer?Enhancer Reprogramming Promotes Pancreatic Cancer Metastasis.Two cases of pancreatic ductal adenocarcinoma with intrapancreatic metastasis.The fatal attraction between pro-prion and filamin A: prion as a marker in human cancers.Transcriptional regulation of urokinase-type plasminogen activator receptor by hypoxia-inducible factor 1 is crucial for invasion of pancreatic and liver cancer.Loss of heterozygosity predicts poor survival after resection of pancreatic adenocarcinoma.Frequency of K-ras mutations in pancreatic intraductal neoplasias associated with pancreatic ductal adenocarcinoma and chronic pancreatitis: a meta-analysisRisk of pancreatic ductal adenocarcinoma in chronic pancreatitis.Oncogenic KRAS activates hedgehog signaling pathway in pancreatic cancer cells.
P2860
Q21144683-CF73387E-9CF0-47D0-9845-0A657AD1A170Q24291505-B429F37B-62B7-4729-94C3-DBA06EE66834Q24805751-005E8746-2AB6-4D2C-BD9F-DC975A2051E6Q28269990-72BC3613-2698-4604-ACF4-631A241FC522Q30465158-670D2224-DCCA-4A5F-9BB3-16E4E4DE2E8FQ33391516-13CD18A8-5A69-4547-B5F0-A17154D6FABBQ33790710-68A44AA8-BA3A-4F4C-9549-F1C6E07E8809Q33855814-90DDF7E1-194D-46C9-96C8-FBDE22D9A3D7Q33943167-3560C92E-487C-4EDC-A8FF-5108426EDF5FQ34127316-E4E276BD-EAFC-4410-B89D-78929F8A28D1Q34642090-2CCF53E5-A25A-432E-A1C5-EFE451A2166FQ34826200-7C8727A0-C58B-4A9E-B835-94AD5CEAD908Q34866662-61CD7976-0526-4931-A460-08C7947A5691Q34894190-1F6444E6-832C-406D-BE24-9E8AD00E9946Q35038199-A55634E9-0EED-48EB-AF40-05B4E2AF7A28Q35766799-A61EE9C1-938A-4C8F-93C7-581D04C331A3Q35801829-C80319C1-942D-452E-814D-D1A6A7DA9782Q35842111-EA81DE1F-8714-41CD-A1E7-390B522EB628Q35842161-2BC0D504-7CB2-47FD-88A3-DB615BD245FDQ36126609-C9B4F583-20DF-4C03-9B84-08A201279853Q36485336-FF227D4C-B51D-436A-886B-62A9C7083B9BQ36723725-55FBF9FB-767F-4F35-B4C9-3856E3C3C0E3Q36829524-A20ED7E2-FF35-45A4-B150-C44BF758F6EAQ36921331-C0BA611E-DFD8-4D38-A77D-2D4DEF457958Q37041763-19765B9A-FCC7-49AB-813B-266829EC6430Q37141651-1606E304-4D78-4917-8823-17329C740DEAQ37153303-D5BAC839-B22D-4CF6-A4EA-C89AEA8BD675Q37218051-2413AC80-E705-4150-AE0A-9516F621E3E4Q37231104-A9054CD3-78DB-4B74-8DDA-62DD3140AA61Q37301411-C2C4EA1D-DBE7-4A5A-B5F1-09E04D5561C5Q37384842-DFEE648B-CAAC-41D8-9365-09C15B6FD40BQ37793368-FA0C2EEC-F02F-4179-8ADB-E00B794314F8Q38696102-ACC942AB-48E8-4A2B-96F3-37CD9B83EEA6Q39022925-B4E27A2C-96C7-4C19-B8A2-1D00A1CFEE03Q39692800-AF656666-BFD2-4D41-AD66-5B65B86D1579Q39889775-BB081859-4DBA-4762-AD2D-ED025D8899A7Q40063344-BD02E67D-4F1E-46E3-B129-3CBE023451D4Q41460315-99AB41B2-ED8A-43C4-8CA7-1D892A0A58C3Q41773506-DD5D66F8-AB03-4783-AB59-A74917F356A7Q42165194-43B6E741-1AA9-4FFE-9A06-65ABC900833B
P2860
Genetic progression and divergence in pancreatic carcinoma
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
2000年论文
@zh
2000年论文
@zh-cn
name
Genetic progression and divergence in pancreatic carcinoma
@ast
Genetic progression and divergence in pancreatic carcinoma
@en
type
label
Genetic progression and divergence in pancreatic carcinoma
@ast
Genetic progression and divergence in pancreatic carcinoma
@en
prefLabel
Genetic progression and divergence in pancreatic carcinoma
@ast
Genetic progression and divergence in pancreatic carcinoma
@en
P2093
P2860
P1476
Genetic progression and divergence in pancreatic carcinoma
@en
P2093
P2860
P304
P356
10.1016/S0002-9440(10)65083-3
P407
P577
2000-06-01T00:00:00Z